Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study

Blood (2023) 142 (Supplement 1): 475.

https://doi.org/10.1182/blood-2023-188032

Published: 2023

Journal Articles

Outcome of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Cytarabine Monotherapy

Jonathan Canaani, MD, Marlise R. Luskin, MD, Alison Loren, MD MS, Colleen Timlin, PharmD, BCOP, James Mangan, MD PhD, Elizabeth O. Hexner, MD, Noelle V. Frey, MDMS, David L Porter, MD, Edward A. Stadtmauer, MD, Selina Luger, MD

Blood (2015) 126 (23): 2543.

https://doi.org/10.1182/blood.V126.23.2543.2543

Published: 2015

Journal Articles

A Clinical Measure of DNA Methylation Predicts Outcome in De Novo AML

Marlise R. Luskin, MD, Phyllis Gimotty, PhD, Catherine Smith, Alison Loren, MD MS, Maria Figueroa, MD, Jenna Harrison, Zhuoxin Sun, PhD, Martin S Tallman, MD, Elisabeth Paietta, PhD, Mark R Litzow, MD, Ross L. Levine, MD, Hugo F. Fernandez, MD, Selina Luger, MD, Martin Carroll, MD, Stephen Master, MD PhD, Gerald Wertheim, MD PhD

Blood (2015) 126 (23): 2591.

https://doi.org/10.1182/blood.V126.23.2591.2591

Published: 2015

Journal Articles

Unrelated Donors Are Associated with Improved Relapse Free Survival Compared to Related Donors in Patients with Myelodysplastic Syndrome Undergoing Reduced Intensity Conditioned Allogeneic Stem-Cell Transplantation

Clinton Yam, MBBS, Lisa Crisalli, BS, Selina Luger, MD, Alison Loren, MD MS, Elizabeth O Hexner, MD, Noelle Frey, MD, James Mangan, MD PhD, Amy Gao, MS, Edward A. Stadtmauer, MD, David Porter, MD, Ran Reshef, MD

Blood (2015) 126 (23): 4380.

https://doi.org/10.1182/blood.V126.23.4380.4380

Published: 2015

Journal Articles

Autologous Stem Cell Transplantation in First Complete Remission May Not Extend Progression Free Survival in Patients with ALK-Negative Peripheral T Cell Lymphoma

Clinton Yam, MBBS, Daniel J. Landsburg, MD, Xinyi Lin, PhD, Anthony Mato, MD, Jakub Svoboda, MD, Alison Loren, MD MS, Noelle Frey, MD, Edward A. Stadtmauer, MD, David Porter, MD, Stephen J. Schuster, MD, Sunita Dwivedy Nasta, MD

Blood (2015) 126 (23): 3183.

https://doi.org/10.1182/blood.V126.23.3183.3183

Published: 2015

Journal Articles

Utilization of Next Generation Sequencing Identifies Potentially Actionable Mutations with Prognostic Significance in Chronic Lymphocytic Leukemia

Jie Wang, MD, Jennifer J.D. Morrissette, PhD, E. Paul Wileyto, PhD, Stephen J. Schuster, MD, Alexandra Vandegrift, BA, Allison Rago, BSN, Colleen Dorsey, BSN, David Porter, MD, Daniel J. Landsburg, MD, Prioty Islam, MD, Sunita Dwivedy Nasta, MD, Jakub Svoboda, MD, Alison Loren, MD MS, Scott Weber, BS, Edward A. Stadtmauer, MD, Anthony Mato, MD

Blood (2015) 126 (23): 2929.

https://doi.org/10.1182/blood.V126.23.2929.2929

Published: 2015

Journal Articles

A Study of Outcomes of Diffuse Large B Cell Lymphoma in the Elderly

Marc Hoffmann, MD, Tahamtan Ahmadi, MD, PhD, Erin Cobain, MD, Alison Loren, Noelle V Frey, David Porter, MD, Edward A. Stadtmauer, MD, Stephen J. Schuster, MD, Sunita D. Nasta, MD

Blood (2011) 118 (21): 4950.

https://doi.org/10.1182/blood.V118.21.4950.4950

Published: 2011

Journal Articles

A Comparison of Two Induction Regimens for Older Patients with Acute Lymphoblastic Leukemia: Daunorubicin, Vincristine and Prednisone (DVP) is Worth Considering

Daniel Landsburg, David Porter, Edward Stadtmauer, Alison Loren, Donald Tsai, Noelle Frey, Steven Goldstein, Elizabeth Hexner, Sunita Dwivedy Nasta, Alexander Perl, Jennifer Davis, Selina Luger

Blood (2010) 116 (21): 3252.

https://doi.org/10.1182/blood.V116.21.3252.3252

Published: 2010

Journal Articles

Reduced Intensity Conditioning with Fludarabine/Busulfan 6.4mg/Kg Results In High Donor Chimerism and Low Toxicity In Both Related and Unrelated Allo-SCT for Hematologic Malignancies.

Steven C Goldstein, MD, Selina M. Luger, MD, Noelle Frey, MD, Alexander Perl, MD, Edward A Stadtmauer, MD, Donald Tsai, MD, Alison Loren, MD, Sunita Nasta, MD, Elizabeth Hexner, MD, Ran Reshef, MD, Jacqueline Smith, CRNP, Joanne Hinkle, Pavel Vassilev, BS, Michael J Vozniak, PharmD, David L. Porter, MD

Blood (2010) 116 (21): 4519.

https://doi.org/10.1182/blood.V116.21.4519.4519

Published: 2010

Journal Articles

Graft-Vs-Lymphoma (GVL) Induction with Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Primary Cutaneous T Cell Lymphomas (CTCL).

Vikram R Paralkar, MD, Sunita Dwivedy Nasta, MD, Kelly Morrissey, MD, Jacqueline Smith, MSN, CRNP, Pavel Vassilev, BS, Mary Ellen Martin, MD, Steven C Goldstein, MD, Alison Loren, MD, MPH, Alain H Rook, MD, Ellen J Kim, MD, David L Porter, MD

Blood (2010) 116 (21): 4574.

https://doi.org/10.1182/blood.V116.21.4574.4574

Published: 2010

Journal Articles

Outcomes of Myeloablative Hematopoietic Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia with Relapsed or Refractory Disease

Courtney D. DiNardo, MD, Alison Loren, MD, Steven Goldstein, MD, Stephen J. Schuster, Alexander Perl, MD, Donald Tsai, MD, Noelle Frey, MD, Elizabeth Hexner, MD, Ran Reshef, MD, Edward A. Stadtmauer, MD, David L. Porter, MD, Selina Luger, MD

Blood (2010) 116 (21): 2366.

https://doi.org/10.1182/blood.V116.21.2366.2366

Published: 2010

Journal Articles

First Report of the Prophylactic Administration of Ex Vivo Co-Stimulated Donor Lymphocyte Infusion (DLI) from Related and Unrelated Donors after Reduced Intensity Conditioning for High Risk Hematologic Malignancies

Steven C Goldstein, MD, Bruce Levine, PhD, Jacqueline Smith, MSN, CRNP, Joanne Hinkle, RN, BSN, OCN, Selina Luger, MD, Alexander Perl, MD, Alison Loren, MD, Noelle Frey, MD, Edward Stadtmauer, MD, Daniel Schullery, PhD, Jean Boyer, PhD, Dennis L. Confer, MD, David Porter, MD, Carl H. June, MD

Blood (2008) 112 (11): 468.

https://doi.org/10.1182/blood.V112.11.468.468

Published: 2008

Journal Articles

Initial Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase I Clinical Trial of Systemic C-MYB Antisense Oligodeoxynucleotide in Subjects with Refractory Hematologic Malignancies

Noelle V Frey, Anna Kalota, Melissa Potuzak, Doris Shank, Cezary R Swider, Alison Loren, Edward Stadtmauer, Alexander Perl, Adam Cuker, Barbara Konkle, Suman Sood, Steven Goldstein, Margaret Kasner, David L Porter, Selina M Luger, Alan M Gewirtz

Blood (2008) 112 (11): 4033.

https://doi.org/10.1182/blood.V112.11.4033.4033

Published: 2008

Journal Articles

Donor Characteristics Affecting Graft Failure and Survival after Unrelated Donor Transplantation with Reduced Intensity Conditioning Regimens (RIC) for Hematologic Malignancies.

Jakob R. Passweg, MD, MS, Fangyu Kan, MS, MA, Mei-Jie Zhang, PhD, Vanderson Rocha, MD, PhD, Luis M. Isola, MD, Adrian P. Gee, PhD, John Gibson, MBBS, FRACP, FRCPA, Hillard M. Lazarus, MD, Mary J. Laughlin, MD, Alison Loren, MD, MS, David Marks, MD, PhD, Alois Gratwohl, Mary Eapen, MBBS

Blood (2008) 112 (11): 1968.

https://doi.org/10.1182/blood.V112.11.1968.1968

Published: 2008

Journal Articles

Systemic Inflammatory Response Syndrome (SIRS) as Predictor of Severe Sepsis (SS) in Hospitalized Patients (pts) with Hematologic Malignancies.

Anthony Mato, MD, Barry Fuchs, MD, Daniel Heitjan, PhD, Erin Olson, MD, Samantha Jacobs, MD, Rosie Mick, David Zheng, Chaitra Ujjani, MD, Andrea Miltiades, Kelly Fabrega, Alicia Morgans, MD, Martin Carroll, MD, Alison Loren, MD, Selina Luger, MD

Blood (2007) 110 (11): 633.

https://doi.org/10.1182/blood.V110.11.633.633

Published: 2007

Journal Articles

A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation

David L. Porter, Bruce L. Levine, Nancy Bunin, Edward A. Stadtmauer, Selina M. Luger, Steven Goldstein, Alison Loren, Julie Phillips, Sunita Nasta, Alexander Perl, Steven Schuster, Donald Tsai, Ambika Sohal, Elizabeth Veloso, Stephen Emerson, Carl H. June

Blood (2006) 107 (4): 1325–1331.

https://doi.org/10.1182/blood-2005-08-3373

Published: 2006

Journal Articles

Non-Myeloablative Conditioning with Allogeneic Progenitor Cell Transplantation for Relapsed Hodgkin’s Lymphoma: High Response Rate Despite Prior Chemoresistance.

Steven C. Goldstein, MD, Selina M. Luger, MD, Edward Stadtmauer, MD, Stephen Schuster, MD, Donald Tsai, MD, PhD, Sunita Nasta, MD, Alison Loren, MD, Alexander Perl, MD, Greg Orloff, MD, Julie Oliver, CRNP, Robert Sachs, Stephen Emerson, MD, PhD, David L. Porter, MD.

Blood (2004) 104 (11): 2258.

https://doi.org/10.1182/blood.V104.11.2258.2258

Published: 2004

Journal Articles

Utility of Prophylactic Autologous Stem Cell Collection for Patients with Acute Myeloid Leukemia in First Remission.

Margie Kasner, MD, Selina Luger, MD, Edward Stadtmauer, MD, Stephen Schuster, MD, Donald Tsai, MD, Sunita Nasta, MD, Alexander Perl, MD, Alison Loren, MD, Steven Goldstein, MD, Patricia Mangan, CRNP, Robert Sachs, Donald Seigel, MD, David Porter, MD

Blood (2004) 104 (11): 1872.

https://doi.org/10.1182/blood.V104.11.1872.1872

Published: 2004

Journal Articles

A Predictive Model for Tumor Lysis Syndrome in Acute Myelogenous Leukemia.

Anthony R. Mato, MD, Brett E. Riccio, MD, Li Qin, PhD, Daniel Heitjan, PhD, Alison Loren, MD, Martin Carroll, MD, David Porter, MD, Donald Tsai, MD, Edward Stadtmauer, MD, Sasha Perl, MD, Alan Gewirtz, MD, Sunita Nasta, MD, Stephen Schuster, MD, Steven Goldstein, MD, Selina M. Luger, MD

Blood (2004) 104 (11): 883.

https://doi.org/10.1182/blood.V104.11.883.883

Published: 2004

Journal Articles

Enhancing Graft-vs-Tumor (GVT) Activity of Donor Leukocyte Infusions by Ex-Vivo Expansion and Activation with CD3/CD28 Co-Stimulation.

David Porter, MD, Bruce Levine, PhD, Nancy Bunin, MD, Edward Stadtmauer, MD, Selina Luger, MD, Steven Goldstein, MD, Stephen Schuster, MD, Donald Tsai, MD, Sunita Nasta, MD, Alison Loren, MD, Alexander Perl, MD, Julie Oliver, CRNP, Ambika Sohal, Liz Veloso, RN, Stephen Emerson, MD, PhD, Carl June, MD

Blood (2004) 104 (11): 1640.

https://doi.org/10.1182/blood.V104.11.1640.1640

Published: 2004

NARROW

Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study

Outcome of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Cytarabine Monotherapy

A Clinical Measure of DNA Methylation Predicts Outcome in De Novo AML

Unrelated Donors Are Associated with Improved Relapse Free Survival Compared to Related Donors in Patients with Myelodysplastic Syndrome Undergoing Reduced Intensity Conditioned Allogeneic Stem-Cell Transplantation

Autologous Stem Cell Transplantation in First Complete Remission May Not Extend Progression Free Survival in Patients with ALK-Negative Peripheral T Cell Lymphoma

Utilization of Next Generation Sequencing Identifies Potentially Actionable Mutations with Prognostic Significance in Chronic Lymphocytic Leukemia

A Study of Outcomes of Diffuse Large B Cell Lymphoma in the Elderly

A Comparison of Two Induction Regimens for Older Patients with Acute Lymphoblastic Leukemia: Daunorubicin, Vincristine and Prednisone (DVP) is Worth Considering

Reduced Intensity Conditioning with Fludarabine/Busulfan 6.4mg/Kg Results In High Donor Chimerism and Low Toxicity In Both Related and Unrelated Allo-SCT for Hematologic Malignancies.

Graft-Vs-Lymphoma (GVL) Induction with Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Primary Cutaneous T Cell Lymphomas (CTCL).

Outcomes of Myeloablative Hematopoietic Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia with Relapsed or Refractory Disease

First Report of the Prophylactic Administration of Ex Vivo Co-Stimulated Donor Lymphocyte Infusion (DLI) from Related and Unrelated Donors after Reduced Intensity Conditioning for High Risk Hematologic Malignancies

Initial Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase I Clinical Trial of Systemic C-MYB Antisense Oligodeoxynucleotide in Subjects with Refractory Hematologic Malignancies

Donor Characteristics Affecting Graft Failure and Survival after Unrelated Donor Transplantation with Reduced Intensity Conditioning Regimens (RIC) for Hematologic Malignancies.

Systemic Inflammatory Response Syndrome (SIRS) as Predictor of Severe Sepsis (SS) in Hospitalized Patients (pts) with Hematologic Malignancies.

A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation

Non-Myeloablative Conditioning with Allogeneic Progenitor Cell Transplantation for Relapsed Hodgkin’s Lymphoma: High Response Rate Despite Prior Chemoresistance.

Utility of Prophylactic Autologous Stem Cell Collection for Patients with Acute Myeloid Leukemia in First Remission.

A Predictive Model for Tumor Lysis Syndrome in Acute Myelogenous Leukemia.

Enhancing Graft-vs-Tumor (GVT) Activity of Donor Leukocyte Infusions by Ex-Vivo Expansion and Activation with CD3/CD28 Co-Stimulation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only